Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar:361:104280.
doi: 10.1016/j.cellimm.2020.104280. Epub 2020 Dec 31.

Importance of myeloid derived suppressor cells in cancer from a biomarker perspective

Suresh Gopi Kalathil  1 , Yasmin Thanavala  2
Affiliations
Review

Importance of myeloid derived suppressor cells in cancer from a biomarker perspective

Suresh Gopi Kalathil et al. Cell Immunol. 2021 Mar.

Abstract

Myeloid derived suppressor cells (MDSC) are a heterogenous population of immature myeloid cells that accumulate in tumor bearing host and migrate to lymphoid organs and tumor tissues. This process is controlled by a set of defined pro-inflammatory cytokines and chemokines, which are upregulated in malignancies. MDSC have strong immunosuppressive potential and constitute a major component of the tumor microenvironment (TME). Tumor cells take advantage of the suppressive mechanisms of MDSC to establish an immunosuppressive TME which inhibits antitumor immune responses thereby promoting cancer progression. An immunosuppressive TME acts as a significant barrier to immunotherapeutic interventions. Pre-clinical and clinical studies have demonstrated that enrichment and activation of MDSC is correlated with tumor progression, recurrence and metastasis. In this review we discuss the potential impact of MDSC on tumor progression and its role as a biomarker of prognostic significance in cancer with a special focus on hepatocellular cancer (HCC).

Trial registration: ClinicalTrials.gov NCT01835223.

Keywords: Biomarker; HCC; Immunotherapy; MDSC; Tumor microenvironment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H, The terminology issue for myeloid-derived suppressor cells, Cancer Res, 67 (2007) 425; author reply 426. - PMC - PubMed
    1. Marvel D, Gabrilovich DI, Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected, J. Clin. Invest, 125 (2015) 3356–3364. - PMC - PubMed
    1. Ostrand-Rosenberg S, Fenselau C, Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment, J. Immunol. 200 (2018) 422–431. - PMC - PubMed
    1. Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V, Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression, Front. Immunol. 9 (2018), 10.3389/fimmu.2018.00398. - DOI - PMC - PubMed
    1. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V, Coordinated regulation of myeloid cells by tumours, Nat. Rev. Immunol. 12 (2012) 253–268. - PMC - PubMed

Publication types

MeSH terms

Associated data